Introduction: Nanotechnology structured water is a new type of water that is produced using special modulators to change and add new properties to water molecules.

Objectives: To find out the effect of drinking nanotechnology structured water on blood glucose levels in patients with type 2 diabetes mellitus.

Patients and Methods: Type-2 diabetes mellitus patients (n=387) with only oral hypoglycemic drugs were blindly divided into 2 groups. Group A (191 patients) supplied with nanotechnology structured water and group B (196 patients) supplied with ordinary bottled water. Water bottles were unlabeled and patients were unaware of the type of water given to them. Blood glucose level was measured as Glycated Hemoglobin (HbA1c) in the same laboratory. Tests were done before starting drinking the water given to the patients as baseline then measured at the end of the third month of drinking the given water in a daily dose of (500 ml /25 kg of body weight).

Results: At the end of the the study, only 352 patients were followed (35 patients dropped out for different reasons). Group A (n=183) (aged 24 to 76, mean 50.2) years with male to female (56.3%: 43.7%), and group B (n=169) (aged 30 to77, mean49.3) years with male to female (49.1%:50.9%). Group A showed significant difference between baseline HbA1c 8.1%+/-1.38 vs. HbA1c after 3 months 6.6%+/-0.85 (p<0.001). While group B showed no significant difference in pre-post HbA1c tests 7.9% +/-1.36 vs. 7.8% +/-1.16 (p=0.274). The percentage of Patients with HbA1c<7 in group A increased from (25.1%) at baseline to (61.2%) after 3 months, while in group B, the percentage of patients with HbA1c <7 decreased from (27.2%) to (19.5%).

Conclusion: Nanotechnology structured water magnalife offers a new way to achieve better control of blood sugar in type 2 diabetic patients. However, further studies are needed to study the long term use of nano-water for the possibility to gradually decrease the needed doses of hypoglycemic agents or to stop them.

Disclosure

A.K. M. Sami: None. K.H. Amin: None. M.T. Kurmanji: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.